シノハラ　アキヒト   SHINOHARA Akihito   篠原　明仁    所属   医学部 医学科（東京女子医科大学病院）    職種   講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma.
掲載誌名	正式名：Bone marrow transplantation 略　 称：Bone Marrow Transplant ISSNコード：14765365/02683369
掲載区分	国外
巻・号・頁	59(12),pp.1735-1743
著者・共著者	Nishikubo Masashi†, Shimomura Yoshimitsu, Nakaya Yosuke, Shinohara Akihito, Uchida Naoyuki, Takayama Nobuyuki, Kobayashi Hikaru, Uehara Yasufumi, Ishikawa Jun, Ishiwata Kazuya, Hiramoto Nobuhiro, Nakazawa Hideyuki, Kataoka Keisuke, Kanda Junya, Nagafuji Koji, Kozai Yasuji, Matsuhashi Yoshiko, Ishimaru Fumihiko, Kim Sung-Won, Fukuda Takahiro, Kanda Yoshinobu, Atsuta Yoshiko, Kondo Eisei, Kako Shinichi
発行年月	2024/12
概要	Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for relapsed or refractory non-Hodgkin lymphoma (R/R NHL). Allo-HSCT using post-transplant cyclophosphamide (PTCY-haplo) and umbilical cord blood transplantation (uCBT) are important donor options in the absence of matched related siblings. However, the data comparing these two donor sources in R/R NHL are limited. Using the Japanese nationwide transplantation registry data, we identified 857 patients with R/R NHL, including 169 patients who received PTCY-haplo and 688 who received uCBT for their first allo-HSCT between January 2013 and December 2021; 514 patients (60%) had B-cell lymphoma. More PTCY-haplo recipients received allo-HSCT using a reduced-intensity conditioning regimen in recent years. The 3-year overall survival (OS), progression-free survival (PFS), and graft-versus-host disease (GVHD)-free/relapse-free survival (GRFS) rates in the PTCY-haplo and uCBT groups were 44% versus 39% (P = 0.326), 34% versus 33% (P = 0.660), and 19% versus 23% (P = 0.910), respectively; the adjusted hazard ratios for OS, PFS, and GRFS were 0.89 (95% confidence interval: 0.69-1.15, P = 0.373), 0.98 (0.78-1.22, P = 0.852), and 0.92 (0.83-1.21, P = 0.920), respectively. The PTCY-haplo group showed faster neutrophil and platelet engraftment and a lower incidence of grade III-IV acute GVHD. Thus, PTCY-haplo and uCBT could serve as alternative donor sources in patients with R/R NHL.
DOI	10.1038/s41409-024-02423-y
PMID	39322651